Samsung Biologics Earns EcoVadis Platinum Sustainability Rating

COMPANY PROFILE
  • Samsung Biologics has received the Platinum Sustainability Rating from EcoVadis, placing it in the top 1% of companies assessed globally.
  • The rating reflects progress across environment, labor and human rights, ethics, and sustainable procurement, following a Gold rating in 2024.

Samsung Biologics announced that it has been awarded the Platinum Sustainability Rating by EcoVadis, the highest level of recognition under the platform’s global sustainability assessment framework. The Platinum rating places the company in the top one percent of all organizations evaluated by EcoVadis worldwide.

EcoVadis assesses corporate social responsibility performance across four categories: environment, labor and human rights, ethics, and sustainable procurement. The rating is widely used by multinational companies, including pharmaceutical firms, as a benchmark for supply chain sustainability and partner selection. Samsung Biologics previously received an EcoVadis Gold rating in 2024.

According to the company, the upgraded rating reflects the continued strengthening of its sustainability management systems and execution across operations and its supply chain. The assessment recognized progress made across all four evaluation categories over the past year.

“This recognition reflects the steady progress we have made in advancing sustainability practices across our operations and supply chain. The company remains focused on responsible business practices to support long-term partnerships.”

John Rim, President and CEO of Samsung Biologics

Samsung Biologics said it has expanded renewable energy use across its operations and reinforced ethical and compliance frameworks as part of its sustainability strategy. In December 2025, the company received an ‘A’ rating in Water Security from the Carbon Disclosure Project, and it continues to engage suppliers on decarbonization initiatives through its participation in the Sustainable Markets Initiative Health Systems Task Force.

CDMO News Analysed

The latest CDMO investments, partnerships, and market intelligence. Download for:

  • Full tracker of partnerships and strategic announcements.
  • Deal value of disclosed investment
  • Regional and modality trends